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Possa SS, Charafeddine HT, Righetti RF, da Silva PA, Almeida-
Reis R, Saraiva-Romanholo BM, Perini A, Prado CM, Leick-
Maldonado EA, Martins MA, Tibério ID. Rho-kinase inhibition atten-
uates airway responsiveness, inflammation, matrix remodeling, and oxi-
dative stress activation induced by chronic inflammation. Am J Physiol
Lung Cell Mol Physiol 303: L939–L952, 2012. First published Septem-
ber 21, 2012; doi:10.1152/ajplung.00034.2012.—Several studies have
demonstrated the importance of Rho-kinase in the modulation of
smooth muscle contraction, airway hyperresponsiveness, and inflam-
mation. However, the effects of repeated treatment with a specific
inhibitor of this pathway have not been previously investigated. We
evaluated the effects of repeated treatment with Y-27632, a highly
selective Rho-kinase inhibitor, on airway hyperresponsiveness, oxi-
dative stress activation, extracellular matrix remodeling, eosinophilic
inflammation, and cytokine expression in an animal model of chronic
airway inflammation. Guinea pigs were subjected to seven ovalbumin
or saline exposures. The treatment with Y-27632 (1 mM) started at the
fifth inhalation. Seventy-two hours after the seventh inhalation, the
animals= pulmonary mechanics were evaluated, and exhaled nitric
oxide (ENO) was collected. The lungs were removed, and histological
analysis was performed using morphometry. Treatment with Y-27632
in sensitized animals reduced ENO concentrations, maximal responses
of resistance, elastance of the respiratory system, eosinophil counts,
collagen and elastic fiber contents, the numbers of cells positive for
IL-2, IL-4, IL-5, IL-13, inducible nitric oxide synthase, matrix met-
alloproteinase-9, tissue inhibitor of metalloproteinase-1, transforming
growth factor-, NF-B, IFN-, and 8-iso-prostaglandin F2 contents
compared with the untreated group (P  0.05). We observed positive
correlations among the functional responses and inflammation, re-
modeling, and oxidative stress pathway activation markers evaluated.
In conclusion, Rho-kinase pathway activation contributes to the po-
tentiation of the hyperresponsiveness, inflammation, the extracellular
matrix remodeling process, and oxidative stress activation. These
results suggest that Rho-kinase inhibitors represent potential pharma-
cological tools for the control of asthma.
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ASTHMA IS AN INFLAMMATORY pulmonary disease characterized by
airway hyperresponsiveness and inflammation, which may be
increased by inflammatory mediators, neurotransmitters and in-
haled contractile stimuli such as allergens and irritant air pollut-
ants (8). These processes lead to cellular and structural changes in
the airways, known as airway remodeling (24, 32, 47).
The most important medications for the control of asthma
are the inhaled corticosteroids. However, these drugs present
several deficiencies, including heterogeneous individual pa-
tient responses and the presence of steroid-resistant processes
in airway inflammation (8). Furthermore, the corticosteroids
are ineffective in reversing airway remodeling and its func-
tional consequences, including a large effect on airway hyper-
responsiveness (7). In this context, there is a growing need for
new alternative therapeutic agents that better regulate the
various processes involved in the pathophysiology of asthma.
Y-27632 [()-(R)-trans-4-(1-aminoethyl)-N-(4-pyrydil) cy-
clohexanecarboxamide monohydrate] is an investigational new
drug for the treatment for asthma. Y-27632 is a highly selective
inhibitor of the Rho-kinase pathway that reverses G protein
sensitization and consequently relaxes the airway smooth mus-
cle (17, 45).
Ca2 sensitization, also observed in the airways, is the
increase in smooth muscle tension and/or phosphorylation of
the 20-kDa regulatory light chain of myosin (MLC20) at a
constant Ca2 concentration (51). This Ca2 sensitization is
mediated in a variety of smooth muscles by a small G protein,
RhoAp21, and its target protein, Rho-kinase (45), which is
especially important during the sustained phase of contraction
in smooth muscle (51).
Several studies have shown that the use of Rho-kinase inhibi-
tors may be beneficial for the treatment of airway diseases.
Experimentally, Rho-kinase appears to be involved in processes
such as modulating the degree (and perhaps the development) of
airway hyperresponsiveness (15, 38, 40), the infiltration of inflam-
matory cells into the airways (38, 43), and the growth factor-
dependent contraction of human airway smooth muscle (9). These
beneficial effects suggest that the inhibition of Rho-kinase signal-
ing may represent a new strategy for resolving airflow limitations
in asthma (51).
The aim of the present study was to evaluate the impact of
the use of repeated treatment with inhaled Y-27632 on airway
hyperresponsiveness, oxidative stress activation, airway extra-
cellular matrix remodeling, eosinophilic inflammation, and T
helper (Th)2 and Th1 cytokine expression in an animal model
of chronic airway inflammation.
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MATERIALS AND METHODS
Animals. We selected 3-wk-old, pathogen-free male Hartley guinea
pigs (GP) with initial weights of 300–350 g as subjects for this study.
The animals received humane care in compliance with National
Institutes of Health guidelines for care and use of laboratory animals.
All protocols and procedures described in this study were approved by
the Institutional Review Board of The University of São Paulo (São
Paulo, SP, Brazil).
Experimental groups. The experimental protocol included four
groups (n  8 for each group): 1) SAL, subjected to the inhalation of
aerosolized normal saline; 2) OVA, exposed to the ovalbumin solution
challenge; 3) SAL-RHO, subjected to the inhalation of aerosolized
normal saline and aerosolized Y-27632, starting with the fifth inha-
lation of saline; and 4) OVA-RHO, exposed to the ovalbumin solution
challenge and aerosolized Y-27632, starting with the fifth inhalation
of ovalbumin.
Induction of chronic allergic pulmonary inflammation. The induc-
tion of chronic airway inflammation was conducted as described
previously (3, 23, 29, 30, 35, 44). In short, the animals were individ-
ually placed in a Plexiglas box (30 cm  15 cm  20 cm) coupled to
an ultrasonic nebulizer (Soniclear, São Paulo, Brazil). An aerosol of
ovalbumin solution (Sigma Chemical, St. Louis, MO) diluted in a
sterile 0.9% NaCl solution (saline) was generated for 15 min or until
respiratory distress occurred. The time that the GP were in contact
with the aerosol was termed “inhalation time”. A protocol of seven
inhalations was conducted twice a week over a period of 4 wk, with
increasing concentrations of ovalbumin (1–5 mg/ml) to avoid the
development of tolerance. In the first 2 wk (challenges 1–4), the dose
of ovalbumin used was 1.0 mg/ml. In the third week (the 5th and 6th
challenges), the animals received a solution containing 2.5 mg/ml of
ovalbumin. In the last week of the protocol (the 4th wk; the 7th
challenge), the dose was increased to 5.0 mg/ml of ovalbumin. The
control animals (the SAL group) were subjected to the same protocol
with aerosolized saline; see Fig. 1 (44).
Y-27632 treatment. Starting on the fifth inhalation of the experi-
mental protocol, the GP were exposed to 2 min of inhalation with 1
mM Y-27632 (Tocris Bioscience, Ellisville, MO) 10 min before each
challenge with ovalbumin or normal saline inhalation. This protocol
was based on a previous report stating that 2-min inhalation of 1 mM
Y-27632 was capable of inhibiting an acetylcholine-induced increase
in lung resistance without altering mean blood pressure (17). The
authors administered acetylcholine 10 min after the inhalation of
Y-27632 and verified that, 1 h after the inhalation of the drug, its
effect on lung resistance was already present. We did not use Y-27632
by intravenous injection at a higher concentration because Uehata
et al. (45) reported that this protocol can decrease mean blood pressure
in hypertensive rats. In our study, on the day of the mechanical
evaluation, Y-27632 inhalation was performed 1 h before the start of
the experiment. We elected to administer the drug via inhalation due
to its direct effect on the respiratory system and to minimize systemic
effects.
Measurement of ENO. Seventy-two hours after the seventh protocol
inhalation and 1 h after the Y-27632 was aerosolized, the GP were
anesthetized with pentobarbital sodium (50 mg/kg, intraperitoneal
injection), tracheostomized, and mechanically ventilated at 60 breaths/
min with a tidal volume of 8 ml/kg using a Harvard 683 ventilator
(Harvard Apparatus, Boston, MA). Next, the exhaled nitric oxide
(ENO) concentration was measured as described previously (23, 30).
In brief, to obtain the ENO, after each animal was stabilized on the
ventilator, a collection bag was attached to the expiratory output of the
ventilator for 3 min. The ENO was measured using a chemilumines-
cence technique with a fast-responding analyzer (NOA 280; Sievers
Instruments, Boulder, CO). Before each measurement, the analyzer
was calibrated with an NO source certified at 47 parts per billion (ppb)
(White Martins, São Paulo, Brazil); a zero NO filter (Sievers Instru-
ments) was attached to the inspiratory input to avoid environmental
contamination.
Pulmonary mechanics evaluation. After the ENO measurement, a
mechanical evaluation was conducted. The tracheal pressure (Ptr) was
measured with a 142PC05D differential pressure transducer (Honey-
well, Freeport, IL) connected to a side tap in the tracheal cannula.
Airflow (V=) was obtained using a pneumotachograph (Fleish, Rich-
mond, VA) connected to the tracheal cannula and to a Honeywell
163PC01D36 differential pressure transducer. Lung volume (V)
changes were determined by digital integration of the airflow signal.
Nine to ten respiratory cycles were averaged to obtain each data point.
The Ptr, V=, and V signals were collected before and after the SAL or
OVA challenge and stored on a microcomputer (30, 35, 36, 44). The
baseline measurements of Ptr and V= were performed after the animal
was stabilized on the ventilator. Subsequently, 2-min challenges with
an aerosol of either ovalbumin (30 mg/mL for the OVA and OVA-
RHO groups) or normal saline (for the SAL and SAL-RHO groups)
were delivered into the inspiratory circuit through the air inlet of the
ventilator. Measurements of Ptr and V= were taken 1 and 3 min after
the start of the first challenge. Respiratory system elastance (Ers) and
resistance (Rrs) values were obtained using the equation of motion of
the respiratory system: Ptr(t)  Ers·V(t)  Rrs·V=(t), where t is time.
Immediately after the end of the mechanical evaluation, a positive
end-expiratory pressure of 5 cmH2O was applied to the respiratory
system, and the airways were occluded at the end of expiration to
maintain the insufflation of the lungs. The GP were then exsangui-
nated via the abdominal aorta, the anterior chest wall was removed,
and the lungs were removed en bloc for morphometric studies and
histological analysis.
Morphometric studies. The removed lungs were fixed with buffered
4% paraformaldehyde for 24 h and then transferred to 70% ethanol.
Random sections representing peripheral areas of the lungs were
processed for paraffin embedding. Histological sections 5 	m thick
were obtained. For the immunohistological experiments, the sections
were deparaffinized and washed three times for 10 min each with
H2O2 10V 3% to inhibit endogenous peroxidase activity. Morpho-
metric analysis was performed with a light microscope with an
integrating eyepiece (with a reticule with 100 points and 50 lines)
using a point-counting technique. As the reticule should be placed
adjacent to the airway wall (10), we selected transversely sectioned
noncartilaginous airways for analysis. Morphometric analysis of the
area of airway wall inflammation was made counting the number of
eosinophils or positive cells between the basal membrane of the
airway epithelium and the airway smooth muscle. Data did not include
the epithelium.
Quantification of eosinophils. For the eosinophil counts, the lungs
were stained with Luna’s eosinophil granule stain (48). Three airways
were randomly selected from each lung section and examined at a
Inhalation 1st 2nd 3rd 4th 5th 6th 7th
72h
Exhaled nitric oxide
Mechanical evaluation
Lungs removed
Y-27632 treatment (1 mM)
OVA solution 1mg/mL 2.5 mg/mL 5 mg/mL
Fig. 1. Timeline of the experimental protocol. The guinea pigs were exposed
to 7 inhalations of ovalbumin solution with increasing doses of antigen or
normal saline, 2 times per week, for 4 wk. From the 1st to the 4th inhalations,
the dose of antigen used was 1 mg/ml; in the 5th and 6th inhalations, the dose
was 2.5 mg/ml, and in the 7th inhalation, the dose of antigen used was 5
mg/ml. The ovalbumin or saline solutions were continuously aerosolized for
either 15 min or until the onset of respiratory distress. Y-27632 treatment was
performed by inhalation of the drug for 2 min at 10 min before each inhalation
with ovalbumin (OVA-RHO group) or normal saline (SAL-RHO group),
starting with the 5th inhalation. 72 h after the last inhalation, the animals were
anesthetized, tracheotomized, and subjected to exhaled nitric oxide (ENO)
collection, the evaluation of pulmonary mechanics, and excision of the lungs
for the morphometric, histological, and histochemical analyses.
L940 Rho-KINASE INHIBITION AND CHRONIC AIRWAY INFLAMMATION
AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00034.2012 • www.ajplung.org
magnification of 1,000. The number of eosinophils was determined
as the number of positive cells in each field divided by the number
contacting the airway wall area (104 	m2).
Quantification of collagen and elastic fibers. The lungs were also
stained with Picrosirius, a method for collagen identification, and
Weigert’s Resorcin-Fuchsin, a method for visualizing elastic fibers.
Three different airways were randomly selected from each lung to
quantify collagen and elastic fiber contents. Quantification was per-
formed by the same method described above. The lung sections were
examined at 1,000 magnification, and the volume proportion of
collagen and elastic fibers was determined by dividing the number
of points contacting collagen or elastic fibers by the total number of
points contacting the tissue in the airway area (between basal mem-
brane of the epithelium and the airway smooth muscle). The results
were expressed as percentages.
Evaluation of cytokine-positive cells. For the cytokine evaluations,
antigen retrieval was performed with citrate solution for 30 min.
Sections were incubated with anti-IL-2, anti-IL-4, anti-IL-5, and
anti-IL-13 (all from Santa Cruz Biotechnology, Santa Cruz, CA) and
left overnight at 48°C diluted in BSA in the proportions 1:200 (IL-5
and IL-13), 1:400 (IL-2), or 1:500 (IL-4). An ABC Vectastain Kit
(Vector Laboratories, Burlingame, CA) was used as the secondary
antibody, and 3,3=-diaminobenzidine (DAB) (Dako Cytomation,
Carpinteria, CA) was used as a chromogen. The sections were coun-
terstained with Harris hematoxylin (Merck, Darmstadt, Germany).
Three airways were analyzed per lung at a magnification of 1,000,
as described above. The positive cells were expressed in cells/unit
area (104 	m2).
Evaluation of iNOS. To detect inducible NO synthase (iNOS) activity,
immunohistochemistry was performed using a labeled streptavidin-biotin
(LSAB) method to visualize iNOS antibody. The antigen retrieval was
performed at high temperature in a citrate buffer at pH 6.00. After this
treatment, the sections were washed in PBS. Sections were incubated
with primary iNOS antibody diluted 1:400 (LabVision; NeoMarkers,
Fremont, CA) and incubated overnight. The sections were then washed in
PBS and incubated with rabbit IgG using the ABCElite Kit (PK-6101;
Vector Laboratories). Next, the sections were again washed, and 3,3=-
DAB (Dako Cytomation) was used as a chromogen. The sections were
washed in flowing water and counterstained with Harris hematoxylin
(Merck). Three airways per lung were analyzed at a magnification of
1,000, as previously described. The number of iNOS-positive cells was
determined as the number of positive cells in each field divided by the
number contacting the airway wall area (104 	m2).
Evaluation of 8-isoprostane-PGF2. Immunohistochemical stain-
ing was performed using an antibody to anti-8-epi-prostaglandin F
(PGF)2 (Oxford Biomedical Research, Rochester Hills, MI) at
a 1:500 dilution. Antigen retrieval was performed with trypsin for
20 min. Subsequently, three washes in PBS were performed for 3 min
each. Sections were incubated with anti-8-epi-PGF2 (1:500) diluted
in BSA overnight. After washes in PBS, the ABC Vectastain kit
(Vector Laboratories) was used to provide a secondary antibody, and
3,3=-DAB (Dako Cytomation) was used as a chromogen. The sections
were counterstained with Harris hematoxylin (Merck). The analysis
was performed on the slides stained for 8-isoprostane by applying the
same point-counting technique described above. We determined the
volume proportion of 8-iso-PGF2 in the airway wall area as the ratio
of the numbers of points falling on 8-iso-PGF2 stained and unstained
tissues. The lung sections were examined at a magnification of
1,000, and the results were expressed as percentages.
Evaluation of actin. The immunohistochemistry to detect actin
utilized the LSAB method for the detection of human smooth-muscle
actin markers (Dako). Antigen retrieval for the smooth-muscle actin
marker was performed at high temperature in a citrate solution at pH
6.0 for 30 min. After this treatment, the sections, still immersed in the
same solution, were cooled to room temperature for 20 min and
washed in PBS three times. Before the incubation with the primary
antibody, protein blocking with 2% skim milk was performed for 10
min. The sections were then washed again in PBS and incubated with
the LSAB Plus-HRP kit (Dako). The chromogen used was again
3,3=-DAB (Dako). Finally, the sections were washed in water and
counterstained with Harris hematoxylin (Merck). Analyses were per-
formed by applying the same point-counting technique described
above. The proportion of actin in the area of the airway wall was
obtained as the ratio between the numbers of coinciding points on
actin and unstained tissue. The sections were examined at a magnifi-
cation of 1,000, and the results were expressed as percentages.
Evaluation of TIMP-1. The immunohistochemistry used for the
tissue inhibitor of metalloproteinase (TIMP)-1 assay utilized the per-
oxidase enzyme. Antigen retrieval was performed at a high tempera-
ture in a citrate buffer at pH 6.0 for 1 min. After this treatment, the
sections were washed in flowing water, distilled water, and PBS.
Subsequently, endogenous peroxidase blocking was performed with
methanol V/V and H2O2 10V 3% for 10 min and then with H2O2 10V
3% only three times for 5 min each. The sections were then washed
again with flowing water, distilled water, and PBS. After the blocking,
a TIMP-1 monoclonal antibody (Lab Vision) diluted 1:50 in BSA was
applied to the sections and incubated from 2°C to 8°C overnight
for at least 12 h. The sections were then washed in PBS and incubated
with the Novolink Polymer Kit (Novocastra, Newcastle, UK). After
this step, the sections were washed in PBS and 3,3=-DAB (Sigma
Chemical) was used as a chromogen. Finally, the sections were
washed with water and counterstained with Harris hematoxylin
(Merck). Three airways were analyzed per lung at a magnification of
1,000, as described above. The number of positive cells was
expressed as cells/unit area (104 	m2).
Evaluation of MMP-9, TGF-, NF-B, and IFN-. The immuno-
histochemistry to detect cells expressing matrix metalloproteinase
(MMP)-9, transforming growth factor (TGF)-, NF-B, and IFN-
followed procedures similar to those described above using the LSAB
method. Antigen retrieval was achieved at a high temperature. After
this treatment, the sections were washed in flowing water, deionized
water, and PBS. After blocking, primary monoclonal antibodies di-
luted in BSA were applied over the sections in the following ratios
and incubated overnight: MMP-9, 1:500 (Lab Vision); TGF-,
1:1,500 (Santa Cruz Biotechnology); NF-B, 1:50 (Santa Cruz Bio-
technology); and IFN-, 1:50 (Santa Cruz Biotechnology). The sec-
tions were then washed in PBS and incubated. After this step, the
sections were washed in PBS and visualized with the 3,3=-DAB
chromogen (Dako Cytomation). Finally, the sections were washed in
flowing water and counterstained with Harris hematoxylin (Merck).
Three airways were analyzed per lung at a magnification of 1,000,
as described above. The number of positive cells was expressed as
cells/unit area (104 	m2).
Passive cutaneous anaphylaxis. For the titration of the IgG1 and
IgE antibodies, we used the technique of Ovary (1964) as modified by
Mota and Perini (28). Three GP from each group were anesthetized
with pentobarbital sodium (50 mg/kg ip), and 5 ml of blood was
drawn by cardiac puncture. The blood was centrifuged at 1,000 rpm
for 20 min at a temperature of 4°C. For the IgG1 titration, a portion
of the sample was heated in a water bath at 56°C for 1 h to inactivate
IgE antibodies. The backs of the GP were trichotomized, taking care
to not irritate the skin. Aliquots of 0.1 ml of each concentration of
serum (from 1:5 to 1:2,560) were injected into the dorsal subcutane-
ous tissues of the GP. After 24 h for IgG1 and 10 days for IgE, a
solution containing 1 mg of ovalbumin, 1 mg of Evans blue, and
0.25% saline was injected into the bloodstream. After 30 min, the
animals were killed, their skin removed and inverted, and the diam-
eters of the reactions were analyzed, with reactions larger than 5 mm
in diameter considered to be positive. The titer was determined as the
highest dilution of serum that induced a passive cutaneous anaphy-
lactic reaction.
Statistical analysis. All data are reported as the means 
 SE. The
statistical significance of differences between groups was determined
by ANOVA followed by the Holm-Sidak method for multiple com-
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parisons. We also obtained the Pearson correlation coefficient (R) to
assess the associations of the Rrs and Ers scores with the markers for
remodeling, inflammatory cells, and oxidative stress. All statistical
analysis was performed using SigmaStat software (Systat Software,
San Diego, CA). Differences were considered significant when P 
0.05.
RESULTS
Inhalation time. There were no differences in the inhalation
times among the groups studied until the fourth inhalation, and
all animals reached 15 min of inhalation. None of the normal
saline groups (SAL and SAL-RHO groups) presented respira-
tory distress during the seven inhalations. From the fifth to
seventh inhalation, sensitized and untreated animals (the OVA
group) presented lower inhalation times compared with the
group that was sensitized and treated with Y-27632 (OVA-
RHO group) (8.87 
 2.59 min and 12.52 
 2.9 min, respec-
tively; P  0.05).
ENO. Figure 2 presents the levels of ENO measured at 72 h
after the last inhalation with saline or OVA challenge. The
concentrations of ENO were higher in the OVA group (27.9 

1.92 ppb) than in the SAL (15.9 
 0.69 ppb) and SAL-RHO
(14.5 
 0.88 ppb) groups (P  0.001). The treatment with
Y-27632 reduced the ENO of the OVA-RHO group (20.2 

2.55 ppb) compared with the OVA group (P  0.05).
Pulmonary mechanical evaluation. There were no differences
in the baseline values of the respiratory system resistance and
elastance among the experimental groups (see Table 1). The
percentage of maximal increase of Rrs is illustrated in Fig. 3A.
There was a significant increase of %Rrs in the OVA group
(141.86
 6.6%) compared with the controls (SAL group: 7.99

1.66%; SAL-RHO group: 6.2 
 2.74%). The treatment of sensi-
tized animals with the Rho-kinase inhibitor attenuated this re-
sponse (OVA-RHO group: 7.68 
 2.69%; P  0.001).
The percentage of maximal increase of Ers is shown in Fig.
3B. There was also a significant increase of %Ers in the OVA
group (10.88 
 2.12%) compared with the control groups
(SAL: 3.20 
 0.19%; SAL-RHO: 2.39 
 0.13%). The inhibi-
tion of Rho-kinase reduced this response compared with the
OVA group (OVA-RHO group: 2.28 
 0.21%; P  0.001).
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Fig. 3. Vertical bar graph showing the means 
 SE of the maximal percentage
increases in respiratory system resistance (Rrs) (A) and elastance (Ers) (B)
obtained after airway challenge with ovalbumin (30 mg/ml) or normal saline in
anesthetized guinea pigs. *P 0.001 compared with the SAL, SAL-RHO, and
OVA-RHO groups; **P  0.001 compared with the OVA group.
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Fig. 2. Vertical bar graph representing the means 
 SE of the ENO concen-
trations of the anesthetized guinea pigs. The ENO was collected 72 h after the
7th inhalation (before the challenge) with saline or OVA solutions in the 4
experimental groups. *P  0.05 compared with the other groups; **P  0.05
compared with OVA group.
Table 1. Baseline values of the Rrs and Ers among the
experimental groups
Group Rrs, cmH2O  ml1  s Ers, cmH2O/ml
SAL 0.23 
 0.01 2.64 
 0.16
OVA 0.20 
 0.02 2.50 
 0.22
SAL-RHO 0.11 
 0.01 2.23 
 0.10
OVA-RHO 0.25 
 0.05 1.82 
 0.22
Values are means 
 SE. SAL, saline group; OVA, ovalbumin group; RHO,
Rho-kinase group; Rrs, respiratory system resistance; Ers, respiratory system
elastance.
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Thinking that the effects of Y-27632 on airway responsive-
ness could be an acute effect, we chose to create one more
experimental group. This new group (OVA-wfRHO  OVA-
without final RHO) followed the same protocol of the preced-
ing groups but did not receive the last inhalation of the
inhibitor (performed until 1 h before lung mechanics evalua-
tion). The difference was maintained in %Rrs OVA-wfRHO
group (21.47 
 5.71%) compared with OVA group (P 
0.001). The %Ers difference between the OVA-wfRHO group
(2.53 
 0.38%) and OVA group also remained (P  0.001).
Morphometric analysis. The volume proportion of elastic
fibers is illustrated in Fig. 4A. The elastic fiber contents were
higher in the OVA-exposed animal groups (OVA: 8.01 

0.63%; and OVA-RHO: 4.09 
 0.45%) compared with the
saline-exposed GP (SAL group: 1.38 
 0.63%; SAL-RHO
group: 1.45 
 0.47%; P  0.001). The animals treated with
Y-27632 presented lower elastic fiber contents than the sensi-
tized and untreated animals (OVA-group; P  0.05).
There was an increase in the collagen contents in the airways
of the ovalbumin-exposed GP (OVA: 22.57 
 1.24%; OVA-
RHO: 14.09 
 2.65%) compared with the saline-exposed ones
(SAL: 13.64 
 1.59%; SAL-RHO: 14.45 
 2.09%). The
treatment with Y-27632 also attenuated the collagen fiber
content in the ovalbumin-exposed animals (P  0.05). These
data are presented in Fig. 4B.
Figure 5 shows the values of eosinophil density in the
airways of the four experimental groups. We observed an
increase in eosinophil density in the ovalbumin-exposed GP
(OVA: 27.42 
 4.95 cells cells/104 	m2) compared with the
controls (SAL: 6.67 
 1.38 cells/104 	m2; SAL-RHO: 4.57 

0.44 cells/104 	m2; P  0.001). The treatment with the
Rho-kinase inhibitor reduced the numbers of these cells in the
animals exposed to ovalbumin challenge (OVA-RHO: 13.26

1.39 cells/104 	m2; P  0.05). The values of eosinophil
density were also verified for the OVA-wfRHO group, and the
difference to OVA group was retained (P  0.05).
Figure 6A presents the numbers of IL-2-positive cells for all
experimental groups. There was increase in IL-2-positive cells
in the airways of the untreated ovalbumin-sensitized animals
(the OVA group: 33.07 
 0.72 cells/104 	m2) compared with
the groups exposed to inhalation with saline solution (SAL
group: 2.86 
 0.72 cells/104 	m2; SAL-RHO group: 6.70 

1.12 cells/104 	m2; P  0.001). The number of IL-2-positive
cells in the OVA-exposed group that was also treated with
Y-27632 was reduced (OVA-RHO group: 11.08 
 0.87 cells/
104 	m2; P  0.001).
We also observed (Fig. 6B) an increase in the number of
IL-4-positive cells in untreated animals exposed to ovalbumin
challenges (OVA group: 14.44 
 1.16 cells/104 	m2) com-
pared with the animals of the control groups (SAL: 3.19
 0.90
cells/104 	m2; SAL-RHO: 2.59 
 0.74 cells/104 	m2) and the
treated group (OVA-RHO: 8.53 
 1.13 cells/104 	m2), for
which we observed an attenuation of the IL-4-positive cell
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 SE of the eosinophil densities
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counts (P  0.001). Despite this attenuation of the number of
IL-4-positive cells in the treated animals, there was a differ-
ence in the values of this group in relation to the control group
(P  0.001).
Figure 6C shows the number of IL-5-positive cells in the
airways of the GP of the four experimental groups. We ob-
served an increase in the number of IL-5-positive cells in the
airways of the ovalbumin-sensitized animals (OVA group:
19.86 
 2.49 cells/104 	m2 and OVA-RHO group: 14.42 

1.71 cells/104 	m2) compared with the controls (SAL group:
5.17 
 0.50 cells/104 	m2; SAL-RHO group: 5.68 
 0.25
cells/104 	m2; P  0.001). We observed reduced numbers of
IL-5-positive cells in the airways of the GP sensitized to
ovalbumin and treated with Y-27632 in relation to the OVA
group animals (P  0.05), although there was a significant
difference between the treated animals and the control group (P
0.001).
The numbers of IL-13-positive cells are illustrated in Fig.
6D. The group of GP exposed to ovalbumin presented a higher
number of IL-13-positive cells (OVA: 13.39 
 1.85 cells/104
	m2) than the groups exposed to saline (SAL: 8.40 
 1.28
cells/104 	m2; SAL-RHO: 6.22 
 1.34 cells/104 	m2; P 
0.05). Ovalbumin-exposed GP that received treatment with the
Rho-kinase inhibitor presented a reduced number of IL-13-
positive cells (OVA-RHO group: 8.71 
 0.72 cells/104 	m2)
compared with the OVA group (P  0.05).
We also observed (Fig. 6E) an increase in the number of
cells positive for IFN- in the untreated animals exposed to
ovalbumin challenges (OVA group: 32.14 
 1.5 cells/104
	m2) compared with the control groups (SAL: 16.31 
 1.46
cells/104 	m2; RHO-SAL: 16.53 
 1.94 cells/104 	m2) and
the group treated with the Rho-kinase inhibitor (OVA-RHO:
19.58 
 2.09 cells/104 	m2), for which we observed an
attenuation of IFN--positive cells (P  0.001).
The measurements of the iNOS-positive cells are presented
in Fig. 7A. The number of iNOS-positive cells was signifi-
cantly higher in the untreated ovalbumin-exposed animals
(OVA group: 14.69 
 1.09 cells/104 	m2) compared with the
saline-exposed animals (SAL group: 9.65 
 1.37 cells/104
	m2; SAL-RHO group: 9.05 
 0.7 cells/104 	m2; P  0.05)
and the Y-27632-treated animals exposed to ovalbumin (OVA-
RHO group: 10.37 
 0.68 cells/104 	m2; P  0.05).
The volume proportions of 8-iso-PGF2 in the airways of
the GP are illustrated in Fig. 7B. We observed increased
8-iso-PGF2 contents in the airways of the OVA-exposed
animals groups (OVA: 25.93 
 1.62%) compared with the
saline-exposed guinea pigs (SAL group: 16.55 
 2.33%;
SAL-RHO group: 15.73 
 1.89%; P  0.05). The animals
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Fig. 6. Vertical bar graph showing the means
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treated with Y-27632 presented lower contents of 8-iso-PGF2
(OVA-RHO group: 15.58 
 2.97%) compared with both the
sensitized and untreated animals.
The numbers of NF-B-positive cells are presented in Fig. 7C.
The numbers of NF-B-positive cells were significantly higher
in the untreated animals exposed to ovalbumin (OVA group: 15.37

1.72 cells/104 	m2) than in the groups exposed to saline (SAL:
5.12
 0.69 cells/104 	m2; SAL-RHO: 5.05
 0.9 cells/104 	m2;
P  0.001) and the ovalbumin-exposed animals treated with
Y-27632 (OVA-RHO group: 6.58 
 0.92; P  0.001).
There was also statistically significant differences of smooth-
muscle-specific actin present in the airway walls between groups.
We observed increased smooth-muscle-specific actin contents in
the airways of the ovalbumin-exposed animals groups (OVA:
25.75 
 1.31%) compared with the saline-exposed GP (SAL
group: 9.84 
 1%; SAL-RHO group: 9.94 
 0.9%; P  0.001).
and with the sensitized and treated animals (OVA-RHO group:
12.16 
 0.69%; P  0.001).
The numbers of MMP-9-positive cells are shown in Fig. 8A.
There was a significant increase in the number of MMP-9-
positive cells in the OVA group (24.01 
 0.90 cells/104 	m2)
compared with the controls (SAL group: 14.09 
 1.25 cells/
104 	m2; SAL-RHO group: 12.89 
 1.7 cells/104 	m2; P 
0.001). The treatment of the sensitized animals with the Rho-
kinase inhibitor attenuated this response (OVA-RHO group:
13.20 
 1.96; P  0.001).
Figure 8B presents the numbers of TIMP-1-positive cells for
all experimental groups. The number of cells positive for
TIMP-1 also increased in the airways of the untreated animals
exposed to ovalbumin (OVA group: 15.52 
 2.63 cells/104
	m2) compared with the groups exposed to inhaled saline
(SAL group: 5.79 
 1.01 cells/104 	m2; SAL-RHO group:
4.71 
 0.76 cells/104 	m2; P  0.001). The number of
TIMP-1-positive cells in the group exposed to OVA but treated
with Y-27632 was reduced (OVA-RHO group: 9.03 
 0.53
cells/104 	m2; P  0.05).
The number of TGF--positive cells is shown in Fig. 8C.
The group of GP exposed to ovalbumin showed a higher
number of cells positive for TGF- (OVA group: 10.8 
 0.54
cells/104 	m2) than the groups exposed to saline (SAL: 6.95
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0.73 cells/104 	m2; SAL-RHO: 6.14 
 1.21 cells/104 	m2;
P  0.05). The GP exposed to ovalbumin and treated with the
Rho-kinase inhibitor showed a decreased number of TGF--
positive cells (OVA-RHO group: 8.07 
 0.67 cells/104 	m2)
compared with the OVA group (P  0.05).
Table 2 presents the correlations of Rrs and Ers with the
measures for inflammatory cells, remodeling markers, and
oxidative stress markers. We observed significant correlations
among all the parameters evaluated. In relation to the passive
cutaneous anaphylaxis (PCA), there were no detectable IgG1
antibodies in the SAL and SAL-RHO groups. The PCA
showed an increase in specific anaphylactic IgG1 antibodies in
GP exposed to ovalbumin (OVA group; maximum titration,
1:640). This response was reduced in the animals treated with
Y-27632 (OVA-RHO group; maximum titration, 1:160).
Figure 9 shows representative photomicrographs of GP air-
ways stained for cells expressing IL-2, IL-4, IL-5, and IL-13.
The untreated GP subjected to ovalbumin challenge (OVA
group) presented prominent increases in the numbers of all
cytokine-positive cells (Fig. 9, B, F, J, and N) compared with
the unsensitized animals (SAL group: Fig. 9, A, E, I, and M;
SAL-RHO group: Fig. 9, C, G, K, and O) and the animals in
the OVA-RHO group (Fig. 9, D, H, L, and P) receiving
treatment with the Rho-kinase inhibitor.
Representative photomicrographs of the airways of the ani-
mals stained with Picrosirius for collagen content, Weighert
Resorcin-Fuchsin for elastic fiber content, and immunohisto-
chemistry for the volume proportions of actin and 8-iso-PGF2
are shown in Fig. 10. Except for actin content, for which no
difference was found among the groups, all the other fiber
contents were elevated in the untreated ovalbumin-exposed
animals (OVA group; Fig. 10, B, F, J, and N) compared with
the saline-exposed animals (SAL group; Fig. 10, A, E, I, and
M; SAL-RHO group; Fig. 10, C, G, K, and O). The treatment
of the GP exposed to ovalbumin with the Rho-kinase inhibitor
reduced the contents of collagen fibers (Fig. 10D), elastic fibers
(Fig. 10H), and 8-iso-PGF2 (Fig. 10L).
Figure 11 presents photomicrographs of airway walls from
GP in the four experimental groups subjected to Luna staining
for the detection of eosinophil density and immunohistochem-
ical staining for iNOS, NF-B, and IFN- detection. The
animals exposed to ovalbumin (the OVA group) presented
intense eosinophilic infiltration (Fig. 11B) and increased num-
bers of iNOS- (Fig. 11F), NF-B- (Fig. 11J), and IFN-- (Fig.
11N) positive cells compared with the saline-exposed animals
(SAL group; Fig. 11, A, E, I, and N; SAL-RHO group; Fig. 11,
C, G, K, and O). Treatment with Y-27632 decreased the degree
of eosinophilic infiltration (Fig. 11D) and the numbers of
iNOS- (Fig. 11H), NF-B- (Fig. 11L), and IFN-- (Fig. 11P)
positive cells in the ovalbumin-exposed GP.
Representative photomicrographs of immunohistochemical
staining for MMP-9, TIMP-1, and TGF- in the airways of the
four animal groups are shown in Fig. 12. There was an increase
in the numbers of MMP-9-, TIMP-1-, and TGF--positive cells
in the groups of untreated ovalbumin-exposed animals (OVA
group; Fig. 12, B, F, and J, respectively) compared with the
saline-exposed animals (SAL group; Fig. 12, A, E, and I; and
SAL-RHO group; Fig. 12, C, G, and K). Treatment of the GP
exposed to ovalbumin with Y-27632 reduced the numbers of
MMP-9- (Fig. 12D), TIMP-1 (Fig. 12H), and TGF-- (Fig.
12L) positive cells. Note that, although the microscopic anal-
yses were performed at a magnification of1,000, we chose to
present photomicrographs at lower magnifications to better
highlight the differences among the groups.
DISCUSSION
In the present study, we evaluated the role of Y-27632, a
Rho-kinase inhibitor, on oxidative stress, respiratory system me-
chanics, inflammation, and extracellular matrix remodeling in
the airways of GP with chronic allergic airway inflammation. The
results showed that repeated Rho-kinase inhibition reduced the
airway mechanical responses to antigenic challenge, with corre-
lated reductions in ENO, eosinophilic infiltration, the numbers of
IL-2-, IL-4-, IL-5- and IL-13-positive cells, and extracellular
matrix remodeling in the airway wall. Additionally, there was a
significant reduction in the activation of the oxidative stress
pathway, which was also correlated with the attenuation of the
maximum mechanical responses after antigen challenge.
We previously studied this model of chronic allergic pul-
monary inflammation in GP, and the present results confirm
our previous data, demonstrating that the ovalbumin-sensitized
animals required shorter lengths of time in contact with the
antigen during the challenges (23, 31, 44). In addition, these
previous studies confirmed the presence of airway hyperre-
sponsiveness (23, 30, 31, 35), inflammation (31, 32, 35), and
remodeling (30, 32, 35) in the sensitized GP, constituting an
Table 2. Pearson correlations of Rrs and Ers with the
measures for inflammatory cells, remodeling markers, and
oxidative stress markers
Rrs Ers
Inflammatory Cells
Eosinophils 0.585 0.766
0.00673 0.0000810
IL-2 0.706 0.897
0.000509 0.0000000857
IL-4 0.763 0.684
0.0000910 0.000890
IL-5 0.679 0.495
0.00100 0.0264
IL-13 0.699 0.510
0.000605 0.0216
Remodeling markers
Elastic fibers 0.614 0.667
0.00394 0.00131
Collagen fibers 0.462 0.595
0.0402 0.00562
TGF- 0.625 0.636
0.00322 0.00259
TIMP-1 0.640 0.756
0.00237 0.000116
MMP-9 0.795 0.751
0.0000280 0.000137
Oxidative stress markers
NF-B 0.823 0.889
0.00000846 0.000000166
iNOS 0.794 0.663
0.0000292 0.00144
NO 0.720 0.828
0.000346 0.00000643
Isoprostane 0.710 0.687
0.000457 0.000815
For each data set, the top number is the r value, and the bottom is the P
value. TIMP, tissue inhibitor of metalloproteinase; MMP, matrix metallopro-
teinase; iNOS, inducible nitric oxide (NO) synthase.
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interesting model for the study of possible therapeutic strate-
gies for asthma.
The treatment with the Rho-kinase inhibitor was started on
the fifth inhalation to avoid possible interference with the
sensitization process. We also previously demonstrated that, at
this time, the GP were already sensitized and showed an
increase in the level of IgG1-specific anaphylactic antibodies
detected using the PCA technique (44). This elevation of
IgG1-specific antibodies in ovalbumin-exposed groups was
also demonstrated in the present study.
Acute responses to antigen exposure were evaluated by the
time that guinea pigs were able to be in contact with the
ovalbumin aerosol (inhalation time). In this context, treatment
with Rho-kinase inhibitor attenuated this response in the sen-
sitized animals. We reasoned that an acute response to antigen
challenge may be related to several mechanisms including
IL-2                           IL-4              IL-5               IL-13
SAL
OVA
SAL-RHO
OVA-RHO
Fig. 9. Photomicrographs of the results of im-
munohistochemical analyses of airway walls to
detect IL-2 (A–D, 400), IL-4 (E–H, 400),
IL-5 (I–L, 400), and IL-13 (M–P, 400)
from guinea pigs exposed only to saline (A, E,
I, and M) or ovalbumin (B, F, J, and N). The
treated guinea pigs exposed to saline (C, G, K,
and O) or ovalbumin (D, H, L, and P) are also
represented.
Collagen fibers Elastic fibers Actin 8-iso-PGF2α
SAL
OVA
SAL-RHO
OVA-RHO
Fig. 10. Representative photomicrographs of
guinea pig airways stained with Picrosirius
for collagen content (A–D, 400), Weighert
Resorcin-Fuchsin for elastic fiber content
(E–H, 400), actin (I–L, 400), and 8-iso-
PGF2 (M–P, 400). The 4 experimental
groups are represented: SAL (A, E, I, and M),
OVA (B, F, J, and N), SAL-RHO (C, G, K,
and O), and OVA-RHO (D, H, L, and P).
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smooth-muscle responses that were likely modified by Y-27632
treatment.
The repeated treatment with Y-27632 caused a significant
decrease in the level of NO exhaled from ovalbumin-sensitized
GP. Note that this may have occurred due to the acute effects
of Y-27632, used 1 h before ENO measurement.
The ENO is a well-established, noninvasive biomarker of
airway inflammation that can be used for the assessment of
asthma severity, as elevated ENO levels are associated with
continued inflammation both in humans (4, 19) and in animal
models (23, 30, 42). The level of NO detected in the exhaled
air is traditionally used to evaluate the efficacy of new treat-
ments in experimental models of pulmonary inflammation
(32). Interestingly, previous studies have shown that, in the
same model of chronic allergic pulmonary inflammation used
in this study, NO derived from constitutive isoforms acts as a
potent bronchodilator, vasodilator, and protector against colla-
gen fiber deposition around airways and blood vessels (30).
Furthermore, when the NO derived from the inducible NO
synthase isoform was inhibited exclusively, an attenuation of
airway constriction, inflammation, and remodeling processes
was noted, reducing both collagen and elastic fiber deposition
in airways and distal lung parenchyma, suggesting the contri-
bution of another NO isoform to the pathophysiology of
asthma (32, 42).
We also showed that the baseline values of resistance and
elastance of the respiratory system in Y-27632-treated and
-untreated animals were unaltered. However, the maximal
responses to antigen challenge were significantly reduced by
Rho-kinase inhibition in the sensitized animals. There is evi-
dence that Rho-kinase activation regulates actin/myosin con-
tractility, the expression of inflammatory mediators, and leu-
kocyte adhesion, and transmigration across the lung endothe-
lial cells during inflammatory responses (27). It is important to
note that effects on airway smooth-muscle responses may be
one of the most important factors that must be considered in the
development of new therapies for asthma (5).
Several studies have reported the beneficial effects of Rho-
kinase inhibition on airway hyperresponsiveness in sensitized
animals (7, 9, 15, 40, 38, 43, 51). The influence of Rho-kinase on
airway hyperresponsiveness appears to be, at least in part, related
to agonist-mediated Ca2 sensitization. The mechanisms respon-
sible for the Ca2 sensitization have not been fully elucidated, but
recent studies suggest that Rho-kinase is a key protein involved in
the contraction of smooth muscles; therefore, Rho-kinase presents
a potential therapeutic target for asthma therapy (5, 13, 21, 37).
The activated Rho-kinase promotes the phosphorylation of the
myosin light chain and contributes to an increased level of
muscular contraction (5, 40).
The effects of acute inhibition of Rho-kinase in sensitized
animals have been analyzed in several studies (6, 11, 12, 14,
16, 37, 49, 52). Schaafsma et al. (38) showed that inhalation of
Y-27632 at 30 min before and 8 h after allergen challenge in
sensitized GP effectively prevents the development of airway
hyperresponsiveness, after both the early and late airway reac-
tions.
It has also been reported that Y-27632 reduces cholinergic
nerve-mediated contractions in tracheal preparations of GP and
mice in a dose-dependent manner (6). However, as with 2-
adrenoceptor bronchodilators, Y-27632 increases neurotrans-
mitter release from airway cholinergic nerves. The mechanism
responsible for this neurotransmitter release increase remains
unclear (6, 52).
The increases in airway resistance induced by methacholine
in allergic mice are also reduced with intranasal administration
of Y-27632 at least 8 h after instillation of the Rho-kinase
inhibitor (16). Witzenrath et al. (49) verified that the use of
Y-27632 attenuated the methacholine-provoked airway re-
sponse in sensitized lungs.
Eosinophils                 iNOS                      NF-κB                      IFN-γ
SAL
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SAL-RHO
OVA-RHO
Fig. 11. Representative photomicrographs of
guinea pig airways stained with Luna (A–D,
400) and immunohistochemistry results for
iNOS (E–H, 400), NF-B (I–L, 400), and
IFN- (M–P,400). All experimental groups
are represented: SAL (A, E, I, and M), OVA
(B, F, J, and N), SAL-RHO (C, G, K, and O),
and OVA-RHO (D, H, L, and P).
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In addition to reducing airway hyperresponsiveness by pro-
moting smooth-muscle contractility, Rho-kinase appears to
mediate airway hyperresponsiveness induced by lysophospha-
tidic acid (14, 15). The bronchodilating action of Y-27632 was
also studied as an adjuvant for isofluorane, a volatile anesthetic
traditionally used to treat status asmathicus, with effects asso-
ciated with both Ca2-dependent and Ca2-independent con-
traction in airway smooth muscles (12). Hanazaki et al. (11)
reported that the isofluorane-induced relaxation of rat bronchial
smooth muscle was significantly augmented by a subthreshold
concentration of Y-27632.
Assuming that this may have occurred due to the acute effect
of the drug on the airways, once the inhibitor Y-27632 was
used 1 h before collection of data of pulmonary mechanics, we
chose to create one more experimental group (OVA-wfRHO)
that had not received the last inhalation. We verified that there
was no difference in results of the maximal responses of Ers
and Rrs after ovalbumin challenge between the OVA-wfRHO
and OVA-Rho groups. These data confirmed that the initial
obtained results were really related to the repeated use of
Y-27632 during the experimental protocol. Also, it is important
to emphasize that we are not aware of any previous studies
analyzing the effects of repeated Rho-kinase inhibition. We
believe that repeated inhibition complements these studies in a
fundamental way to demonstrate the potential importance of
the Rho-kinase inhibitors in the treatment of asthma. More-
over, the experimental model used herein presents a chronic
allergic inflammation response.
As in previous studies (31, 32, 44), we observed an increase
in the number of eosinophils in the airways of the sensitized
GP. We also noted that the Rho-kinase inhibitor significantly
attenuated this response in the sensitized animals. Furthermore,
we observed that Rho-kinase inhibition attenuated the numbers
of IL-2-, IL-4, IL-5-, and IL-13-positive cells around the
airway walls. Note that it is possible that the effects of
Y-27632 on eosinophilia and cytokine expression can be par-
tially attributed to an acute Rho-kinase inhibition, once the
Rho-kinase inhibitor was used 1 h before collection of lungs
for morphometric analysis. As above described, we compared
the evaluation of eosinophilic infiltration in the new group
OVA-wfRHO, and we did not find any differences between
OVA-RHO and OVA-wfRHO animals. These results suggest
that the repeated Rho-kinase inhibition modulates upstream
signaling events involved in eosinophil recruitment into the
airways during an allergic inflammatory response.
Several studies have suggested that the RhoA/ROCK system
plays a role in eosinophil recruitment and Th-1 and Th-2
cytokine secretion (1, 2, 16). In this regard, Henry et al. (16)
demonstrated that pretreatment with Y-27632 reduced the
number of eosinophils recovered from the bronchoalveolar
lavage (BAL) fluid of OVA-sensitized mice (16).
Taki et al. (43) demonstrated that another Rho-kinase inhib-
itor, fasudil, reduced the numbers of eosinophils in BAL fluid,
airways, and blood vessels. This Rho-kinase inhibitor also
diminished the augmented levels of IL-5, IL-13, and eotaxin in
BAL fluid (43). Aihara et al. (2) showed that Y-27632 sup-
MMP-9 TIMP-1 TGF-β
SAL
OVA
SAL-RHO
OVA-RHO
Fig. 12. Photomicrographs of the results of
immunohistochemical analyses of airway
walls to detect MMP-9 (A–D, 400), TIMP-1
(E–H, 400), and TGF- (I–L, 400). All
experimental groups are represented: SAL (A,
E, and I), OVA (B, F, and J), SAL-RHO (C,
G, and K), and OVA-RHO (D, H, and L).
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pressed the release of Th-1 cytokines and partially suppressed
the release of Th-2 cytokines in healthy persons but reduced
the release of IL-2 and IL-5 in asthmatic patients and weakly
reduced the release of IL-4 and IFN-. In the present study,
Rho-kinase inhibition was associated with significant reduc-
tions in levels of these interleukins and IFN- in animals
sensitized to ovalbumin, indicating that there is indeed an
association between the Rho/Rho-kinase pathway and the re-
lease of these mediators.
In this study, we also demonstrated attenuations of the
number of cells positive for iNOS and the content of 8-iso-
PGF2 in the area of the airway walls of sensitized animals by
Rho-kinase inhibition with Y-27632. Our results are in agree-
ment with those of McGown et al. (25), who investigated
whether the Rho-kinase inhibitor fasudil protected against
LPS-induced vascular leakage and leukocyte adhesion via
NOS pathways. The authors demonstrated that fasudil de-
creased LPS-induced upregulation of iNOS, reducing micro-
vascular inflammation.
In addition, it is well known that iNOS activation may
contribute to peroxynitrite formation, which is an oxidant agent
formed by the interaction of NO and superoxide. Subsequently,
isoprostane generation may result from lipid peroxidation in-
duced by peroxynitrite formation (50). The inhibition of Rho-
kinase caused a reduction in the number of iNOS-positive
cells, which may have contributed to the attenuation of airway
hyperresponsiveness, oxidative stress, and the consequent ex-
tracellular matrix remodeling. Further studies are necessary to
clarify the exact mechanisms of action of Y-27632 on NO and
oxidative stress.
Regarding the assessment of changes in extracellular matrix
remodeling, there was a significant decrease in the contents of
collagen and elastic fibers in the group of ovalbumin-exposed
animals treated with the Rho-kinase inhibitor compared with
the untreated groups. There is evidence that the experimental
model of chronic pulmonary inflammation is associated with
increased contents of collagen and elastic fibers in the airways
and distal parenchyma (3, 24, 29, 42). However, we are not
aware of previous experimental studies evaluating the role of
Rho-kinase inhibition on the remodeling response.
This remodeling results from repair processes in response to
persistent inflammation triggered by proinflammatory media-
tors, metalloproteinases, cytokines, and growth factors (46). In
reducing the number of inflammatory cells, Rho-kinase inhi-
bition by Y-27632 helps to prevent chronic inflammation and
indirectly contributes to a reduction of remodeling, as evi-
denced by the lower contents of collagen and elastic fibers in
the airway walls.
It is feasible that, in addition to indirect effects on fibrosis,
Rho/ROCK signaling is directly involved in profibrotic pro-
cesses, mediated by airway-resident cells. Schaafsma et al. (39)
showed that human airway myocytes express both geranylgera-
nyl transferase 1 (GGT1) and farnesyltransferase (FT), and the
inhibition of GGT1, but not FT, mirrored the suppressive
effects of simvastatin on collagen I and fibronectin expression
and collagen I secretion. The simvastatin and GGTI-286 both
prevented TGF-1-induced membrane association of RhoA, a
downstream target of GGT1, suggesting that simvastatin and
GGTI-286 inhibit synthesis and secretion of extracellular ma-
trix proteins by human airway smooth muscle cells by sup-
pressing GGT1-mediated posttranslational modification of sig-
naling molecules such as RhoA.
Concerning these results, there are several recent studies
suggesting the importance of Rho-kinase modulation on the
remodeling process. Zhou et al. (53) analyzed the effects of
fasudil on high-glucose-induced proliferation of cardiac fibro-
blasts and collagen production. The authors demonstrated that
the activation of Rho-kinase is essential for the synthesis of
collagen, which may be related to a combination of factors,
including the inhibition of the JNK and TGF- pathways,
which are both involved in the fibrosis process.
Kondrikov et al. (20) investigated the role of Rho-kinase and
reactive oxygen species (ROS) in the synthesis of collagen type
I in human and mice lung fibroblasts subjected to hyperoxia in
a model of oxygen toxicity. The authors concluded that oxygen
toxicity induces ROS to separate the guanine nucleotide dis-
sociation inhibitor (a regulator of Rho GTPase activity) from
Rho, which leads to activation of the Rho-kinase pathway and
contributes to increased collagen-I synthesis.
It was previously reported that iNOS inhibition reduces
MMP-9, TIMP-1, and TGF-. In addition to the reduction of
iNOS, we also observed attenuations of the levels of MMP-9,
TIMP-1, and TGF- in the animals treated with the Rho-kinase
inhibitor. These mediators act in the production of collagen and
elastic fibers, thus contributing to extracellular matrix remod-
eling in the airways (47). The reduced level of iNOS-positive
cells in the presence of Rho-kinase inhibition found in the
present study and the reduced content of collagen and elastic
fibers in the treated groups are probably due to the inhibition of
this pathway. The reduced numbers of iNOS-positive cells
when Rho-kinase is inhibited is in agreement with the results of
other studies although the underlying mechanisms are unclear
(25, 41).
There appears to be a relationship between these mediators
and Rho-kinase. Jiang and George (18) demonstrated that the
inhibition of Rho-kinase with Y-27632 prevented the reduction
of NO induction by TGF-2, avoiding inhibition of iNOS,
suggesting that TGF-2 inhibits iNOS expression via the
Rho-kinase pathway in lung epithelial cells.
We also found that the level of another important inflam-
matory mediator, NF-B, was reduced in the sensitized ani-
mals treated with the Rho-kinase inhibitor compared with the
untreated animals. Similarly, Meyer-Schwezinger et al. (26),
when evaluating the role of Rho-kinase in inflammatory renal
injury in mice, found that the inhibition of Rho-kinase was
related to an attenuation of NF-B signaling, resulting in
protection against injury. These data suggest that the NF-B
signaling is also Rho-kinase dependent. The presence of air-
way smooth muscle tissue hypertrophy reinforces the idea that
we used a model of chronic pulmonary inflammation and that
the repeated use of Y-27632 attenuated this response.
The present study has several limitations. We used Rho-
kinase inhibition by Y-27632 in an experimental model of
chronic airway inflammation. We advise caution when extrap-
olating our findings directly to human physiology. However,
our results support the importance of Rho-kinase in airway
hyperresponsiveness, lung inflammatory responses, extracellu-
lar matrix remodeling, and oxidative stress pathway.
Additionally, it is important to note that the GP model is one
of the best animal models for the study of asthma due to the
similar lung anatomy of humans and GP and the presence of
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several characteristics of human asthma such as eosinophilic
inflammatory and remodeling process (34). Additional studies
are needed to elucidate the exact mechanisms responsible for
these changes.
In conclusion, Rho-kinase pathway activation modulates
hyperresponsiveness, inflammation, the extracellular matrix
remodeling process, and oxidative stress activation. These
results suggest that Rho-kinase inhibitors constitute potential
pharmacological tools for the control of asthma.
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